Clinical Trial Update: A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status [Phase 4]

View source ↗

Summary

A Phase 4 study of rituximab in combination with fludarabine and cyclophosphamide in chronic lymphocytic leukemia was terminated; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Fludarabine (Fludarabine)
• Rituximab (rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lymphocytic Leukemia, Chronic | Phase 4 | Status: TERMINATED | Results posted: 2018-03-20